Imbruvica® (ibrutinib) package insert updates to dose modifications for adverse reactions and to warnings and precautions

A Dear Healthcare Professional Letter has been issued by Johnson & Johnson Pte Ltd to inform healthcare professionals of important updates to the “Dose Modifications” and “Warnings and Precautions” sections of the Singapore package insert for Imbruvica^® (ibrutinib). The updated dose modification recommendations for adverse reactions may reduce the occurrence of additional serious events and are intended to improve tolerability for continued Imbruvica^® treatment. In addition, the revised “Warnings and Precautions” section carries additional information on cardiac arrhythmias, cardiac failure, and sudden fatal cardiac events, including a description of risk factors and guidelines for assessment and management to help prescribers better manage patients at risk. Healthcare professionals are advised to review and follow the updates to the Imbruvica^® Singapore package insert. Please refer to the letter for details. Published: 27 Sep 2022

Dear Healthcare Professional Letters